METTL1 orchestrates tumor immune evasion across multiple cancers by modulating immunosuppressive microenvironments through distinct mechanisms, positioning it as a promising therapeutic target to enhance immunotherapy efficacy. The gene discussed is METTL1; the disease is neoplasm.